BALTIMORE--(BUSINESS WIRE)--May 30, 2006--Profectus BioSciences, Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality caused by viral diseases, today announced that it has completed an additional $3 million private equity placement with the sale of securities to private investors led by Cross Atlantic Capital Partners.
